Clinic of Rheumatology, University Hospital "St. Ivan Rilski", Medical University of Sofia, 13 Urvich str, 1612, Sofia, Bulgaria.
Rheumatol Int. 2020 Nov;40(11):1753-1762. doi: 10.1007/s00296-020-04698-y. Epub 2020 Sep 15.
The novel coronavirus outbreak induces many concerns about the management of pregnancy, as well as rheumatic and musculoskeletal diseases. The very rapid spread of the infection throughout all inhabited continents leads to a fast-growing number of infected with SARS-CoV-2 and requires answers and special recommendations to the most vulnerable group of people: pregnant woman and patients on immunomodulatory or immunosuppressive treatment. A systematic literature search was performed in Embase, MEDLINE, and Scopus database for studies describing COVID-19 infection in pregnant women diagnosed with rheumatic and musculoskeletal diseases. From the 1,115 initially identified articles, we selected 29 publications in the English language, from which 18 were eligible according to the inclusion criteria. Limited number of cases and further researches are required to evaluate the risk of transmission of SARS-CoV-2 from mother to her infant as well as clinical features of infection in pregnant women. The conclusions of different authors, despite the small number of cases, suggest that there is no vertical transmission in women diagnosed with COVID-19 pneumonia. Although the World Health Organization recently reported that pregnant patients do not have a higher risk of infection than the rest of the population, Royal College of Obstetricians & Gynecologists and The Royal College of Midwives for COVID-19 infection in pregnancy published Guidelines for pregnant women with suspected SARS-CoV-2 infection.Considerations about patients with rheumatic diseases on the immunosuppressive treatment required European League Against Rheumatism, American College of Rheumatology, British Society for Rheumatology, and Australian Rheumatology Association to publish recommendations for patients with rheumatic diseases and COVID-19. These algorithms are very important to the medical society, but many concerns, absence of experience, and many questions are still unanswered and need time to be resolved and proceed successfully in this global pandemic situation.
新型冠状病毒爆发引发了人们对妊娠和风湿及肌肉骨骼疾病管理的诸多关注。这种感染在所有有人居住的大陆迅速传播,导致感染 SARS-CoV-2 的人数迅速增加,这需要对最脆弱的人群(孕妇和接受免疫调节或免疫抑制治疗的患者)给出答案和特殊建议。我们在 Embase、MEDLINE 和 Scopus 数据库中进行了系统的文献检索,以查找描述风湿和肌肉骨骼疾病孕妇 COVID-19 感染的研究。在最初确定的 1115 篇文章中,我们选择了 29 篇英文出版物,其中 18 篇符合纳入标准。需要进一步研究以评估 SARS-CoV-2 从母亲传播给婴儿的风险以及孕妇感染的临床特征。尽管病例数量有限,但不同作者的结论表明,诊断为 COVID-19 肺炎的女性没有垂直传播。尽管世界卫生组织最近报告称,感染 COVID-19 的孕妇的感染风险并不高于其他人群,但皇家妇产科医师学院和皇家妇产科学院为 COVID-19 感染孕妇发布了 SARS-CoV-2 感染孕妇指南。对于接受免疫抑制治疗的风湿疾病患者,这些考虑因素导致欧洲抗风湿病联盟、美国风湿病学会、英国风湿病学会和澳大利亚风湿病协会发布了针对风湿疾病和 COVID-19 患者的建议。这些算法对医学界非常重要,但许多关注点、缺乏经验和许多问题仍未得到解答,需要时间在这种全球大流行的情况下得到解决并取得成功。